Core Insights - The article discusses the performance and future outlook of Aquestive Therapeutics (NASDAQ: AQST), noting a 2% decline in the stock price over the past six months since the last analysis [2]. Company Focus Areas - The company is focusing on five key areas for 2025, including the potential FDA approval of Anaphylm, which is a significant catalyst for future growth [2]. Investment Group Features - The investment group Compounding Healthcare offers several features such as model healthcare portfolios, a weekly newsletter, a daily watchlist, and a platform for dialogue and questions among members [2].

WARREN, N.J., June 25, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that two poster presentations highlighting results from the investigational use of Anaphylm™ (epinephrine) Sublingual Film in the treatment of severe allergic reactions, including anaphylaxis, will be presented at the Cent ...

Group 1 - The company has a strong academic foundation with an MBA in Finance and an MD, enhancing its expertise in the financial sector [1] - The firm specializes in income investing and biotech/pharma investing, with nearly a decade of experience in these areas [2] - The organization focuses on identifying both short-term catalyst-driven opportunities and long-term investment strategies in the biotech sector [3] Group 2 - Subscribers receive regular portfolio trade alerts and have access to an interactive chat feature, promoting engagement and addressing inquiries [4] - The company has published a best-selling book on biotech investing and offers an online course, showcasing its commitment to educating investors [4] - The firm provides custom biotech analysis upon request, ensuring tailored insights for its audience [3][4]

First Quarter 2025 Earnings Supplemental Materials September 2024 May 12, 2025 Advancing medicines. Solving problems. Improving lives. Advancing medicines. Solving problems. Improving lives. Advancing medicines. Solving problems. Improving lives. Advancing medicines. Solving problems. Improving lives. ® Disclaimer Certain statements in this press release include "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "believe," "anticipate," "pl ...

Submitted NDA for Anaphylm™ (epinephrine), the first and only oral sublingual film for patients with severe allergic reactions Advancing commercial readiness efforts with a planned Q1 2026 launch of Anaphylm, subject to FDA approvalCompany to host investor call on May 13, 2025, at 8:00am ET WARREN, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives t ...